Africa’s position in the global drug development landscape is transforming. Increasingly, sponsors are viewing the region through the lens of opportunity, especially where vaccines and biologics are concerned. High disease prevalence, especially from infectious diseases, neglected tropical diseases, and increasing non-communicable diseases represents opportunity for clinical development targeting conditions including malaria, HIV/AIDS, and tuberculosis, which can often be under-researched in other regions. Opportunity to diversify trial populations and reduce enrolment timelines are also drivers contributing to Africa’s status as an emerging clinical trial hotspot, as is regulatory and infrastructure improvements and growing investment. So much so that the African clinical trials market size is projected to grow from USD 0.96 billion in 2024 to USD 1.68 billion by 2032, exhibiting a compound annual growth rate of 7.2%.